| Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: a hospital‐based study K Sunami, H Ichikawa, T Kubo, M Kato, Y Fujiwara, A Shimomura, ... Cancer science 110 (4), 1480-1490, 2019 | 305 | 2019 |
| Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors K Fukuoka, Y Kanemura, T Shofuda, S Fukushima, S Yamashita, ... Acta neuropathologica communications 6, 1-18, 2018 | 91 | 2018 |
| Slow-cycling cancer stem cells regulate progression and chemoresistance in colon cancer D Shiokawa, H Sakai, H Ohata, T Miyazaki, Y Kanda, S Sekine, ... Cancer research 80 (20), 4451-4464, 2020 | 57 | 2020 |
| Single-cell DNA and RNA sequencing reveals the dynamics of intra-tumor heterogeneity in a colorectal cancer model H Ono, Y Arai, E Furukawa, D Narushima, T Matsuura, H Nakamura, ... BMC biology 19, 1-17, 2021 | 24 | 2021 |
| Sweepstake evolution revealed by population-genetic analysis of copy-number alterations in single genomes of breast cancer M Kato, DA Vasco, R Sugino, D Narushima, A Krasnitz Royal Society open science 4 (9), 171060, 2017 | 16 | 2017 |
| Japan Pediatric Molecular Neuro-Oncology Group (JPMNG). Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a … K Fukuoka, Y Kanemura, T Shofuda, S Fukushima, S Yamashita, ... Acta Neuropathol Commun 6 (1), 134, 2018 | 13 | 2018 |
| Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model D Narushima, Y Kawasaki, S Takamatsu, H Yamada PeerJ 4, e1753, 2016 | 11 | 2016 |
| Bevacizumab beyond progression for newly diagnosed glioblastoma (BIOMARK): phase II safety, efficacy and biomarker study M Nagane, K Ichimura, R Onuki, D Narushima, M Honda-Kitahara, ... Cancers 14 (22), 5522, 2022 | 4 | 2022 |
| Accurate prediction of functional states of cis-regulatory modules reveals common epigenetic rules in humans and mice P Ni, J Moe, Z Su BMC biology 20 (1), 221, 2022 | 4 | 2022 |
| Sleeping Beauty transposon mutagenesis identified genes and pathways involved in inflammation-associated colon tumor development K Shimomura, N Hattori, N Iida, Y Muranaka, K Sato, Y Shiraishi, Y Arai, ... Nature Communications 14 (1), 6514, 2023 | 2 | 2023 |
| The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology T Kubo, K Sunami, T Koyama, M Kitami, Y Fujiwara, S Kondo, K Yonemori, ... ESMO open 9 (4), 102981, 2024 | | 2024 |
| GCT-34. ELUCIDATION OF THE MECHANISMS OF TUMORIGENESIS IN INTRACRANIAL GERM CELL TUMOR BY WHOLE GENOME SEQUENCE Y Yamagishi, H Takami, D Narushima, Y Matsushita, E Sugihara, ... Neuro-Oncology 22 (Suppl 3), iii334, 2020 | | 2020 |
| ACTR-04. BIOMARK: A PHASE II STUDY OF BEVACIZUMAB BEYOND PROGRESSION FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY, EFFICACY AND PROSPECTIVE BIOMARKER ANALYSIS K Ichimura, M Nagane, M Kato, Y Narita, T Aoki, S Tanaka, A Mukasa, ... Neuro-Oncology 21 (Supplement_6), vi12-vi13, 2019 | | 2019 |
| Molecular Classification of Ependymomas-A Japanese Answer K Fukuoka, Y Kanemura, T Shofuda, S Fukushima, S Yamashita, ... PEDIATRIC BLOOD & CANCER 65, S5-S6, 2018 | | 2018 |
| Single-cell DNA and RNA sequencing resolved the dynamics of intra-tumor heterogeneity in a colorectal cancer mouse model H Ono, Y Arai, J Miyamoto, E Furukawa, D Narushima, H Nakamura, ... CANCER SCIENCE 109, 175-175, 2018 | | 2018 |
| Total informatics systems for large-scale cancer clinical sequencing M Kato, E Furukawa, D Narushima, M Nagai, T Kubo, K Sunami, ... CANCER SCIENCE 109, 550-550, 2018 | | 2018 |
| PP159-MON: Application of a Newly Designed Scale for the Evaluation of Causal Relationships of Adverse Events Associated with Dietary Supplements M Kitagawa, H Yamada, K Ide, K Matsumoto, D Narushima, K Umegaki Clinical Nutrition, S188, 2014 | | 2014 |
| Mamoru Kato, Daniel A. Vasco 2, Ryuichi Sugino 3 D Narushima, A Krasnitz | | |
